Drugs in Dev. Psychiatry/Psychology
Phase I/ Phase II
Ireland 
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : RA Capital Management
Deal Size : $125.0 million
Deal Type : Series B Financing
GH Research Announces Closing of $125 Million Oversubscribed Series B Financing
Details : GH Research will use the proceeds to support further clinical development of GH001 (5-MeO-DMT) in Treatment-Resistant Depression (TRD) and to advance GH001 into further clinical development in additional psychiatric and neurological disorders.
Product Name : GH001
Product Type : Controlled Substance
Upfront Cash : Undisclosed
April 13, 2021
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : RA Capital Management
Deal Size : $125.0 million
Deal Type : Series B Financing
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GH001 has the potential to offer an ultra-rapid clearance of symptoms with long-term sustained remission after a single administration session. In the completed Phase 1 healthy volunteer study (GH001-HV-101), GH001 was safe and well-tolerated at the inve...
Product Name : GH001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 19, 2020
Lead Product(s) : Mebufotenin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
